PPARG agonist pioglitazone was reported to target CML cells effectively by down-regulating transcription factors such as STAT5, CITED2, and HIF2a, which are overexpressed in CML stem cells (Prost et al., 2015). Here, EPAS1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.